|

AP203 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • AP Biosciences Inc.1

Indications

  • Locally Advanced or Metastatic Solid Tumors1
  • Head and Neck Squamous Cell Carcinoma (HNSCC)1
  • Non-small Cell Lung Cancer (NSCLC)1
  • Esophageal Squamous Cell Carcinoma (ESCC)1
  • Lung Cancer1

Other1 trial

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.